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Biology of Early Transplant-Related Complications
Sophie Paczesny,1 Maribel Diaz-Ricart,2 Enrique Carerras,2 Kenneth R. Cooke3In the time since the first allogeneic hematopoietic stem cell transplantation (HSCT) was performed over
40 years ago, this life-saving procedure has been used increasingly for patients with hematologic, metabolic,
and malignant diseases. Despite major advances in our understanding of the immunologic processes (both
beneficial and injurious) that are associated with HSCT and improvements in supportive and critical care
medicine, successful outcomes are still limited by several serious complications. As such, the establishment
of effective therapeutic strategies for these complications will be crucial as increasing numbers of high-risk
transplants are performed each year. The development of such approaches is fundamentally dependent
upon a basic understanding of pathophysiologic mechanisms of disease and also on our ability to successfully
translate these insights back to the bedside. This brief review will highlight breakthroughs in translational
research endeavors that have paved the way for the development of novel strategies intended to change the
standard of care and optimize outcomes for patients in whom allogeneic HSCT offers the only hope for
a cure.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative therapy for many patients
with hematologic, metabolic, and neoplastic disorders.
Unfortunately, several complications still negatively
impact outcomes and limit the broader application of
this treatment. Specifically, the development of graft-
versus-host disease (GVHD), idiopathic pneumonia
syndrome (IPS), and sinusoidal obstruction syndrome
(SOS), are associated with significant morbidity1Blood and Marrow Transplantation Program, University
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conditioning is administered. The establishment of ef-
fective strategies to reduce toxicity after HSCT is crit-
ical as increasing numbers of high-risk transplants are
performed each year.TRANSLATIONAL EVIDENCE FOR
ENDOTHELIAL DYSFUNCTION AFTER HSCT
Experimental and clinical data have enhanced our
knowledge of how cellular and soluble effectors
contribute to the pro-inflammatory milieu that is asso-
ciated with acute toxicity following allogeneic HSCT.
Endothelial cell (EC) damage is observed after HSCT
and has been implicated as a common thread to the
development of many of these complications. The
endothelium is an active biologic interface between
the blood and all other tissues, which mediates
vasomotor tone, hemostatic balance, and inflamma-
tory reactions throughout the circulatory system. EC
activation commonly occurs in times of physiologic
stress, may develop locally or systemically, takes place
in a graded (rather than in an ‘‘all or nothing’’) manner,
and differs according to several variables including the
location of the vascular bed [1,2].
During HSCT, ECs can be activated and damaged
by several factors including the chemoradiotherapy,S101
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ucts, medications, and the complex processes of hema-
topoietic engraftment and GVHD. EC injury can be
evaluated through the analysis of soluble markers
including plasma von Willebrand factor (VWF), solu-
ble forms of adhesion molecules, the enumeration of
circulating ECs, and the evaluation of morphologic
and functional changes induced on cultured ECs.
Recently, the effects of HSCT type and conditioning
regimen intensity on the integrity of the endothelium
have been evaluated through a series of in vivo and in
vitro measurements [3].
To determine the kinetics of endothelial damage
after HSCT, plasma samples were obtained from pa-
tients with and without early complications before
(Pre), on day 0, and then weekly through day 21
following autologous (auto-) and allogeneic (allo-)
HSCT. Levels of VWF, ADAMTS-13 activity,
sVCAM-1, sICAM-1, and sTNFRI were measured.
Changes were observed in most markers and followed
different patterns in the auto and allo settings. For
example, progressive increases in VWF and sTNRI,
were observed from day Pre to day 14 and to day 21
after auto- and allo-HSCT, respectively, and
ADAMTS-13 activity inversely correlated with VWF
levels. Levels of sVCAM-1 decreased until day 7, and
subsequently increased significantly by day 14 (auto-
HSCT) and day 21 (allo-HSCT). By contrast, no sig-
nificant changes were detected for sICAM-1. These
results confirmed that evidence for endothelial damage
can be seen in the early phases of HSCT and coincides
with the (1) delivery of HSCT conditioning, (2)
administration of immunomodulatory agents, (3) de-
velopment of mucositis, and (4) onset of donor leuko-
cyte engraftment. Moreover, the degree of the changes
in the biomarkers observed was related to the condi-
tioning regimen intensity. Preliminary data also show
that levels of soluble biomarkers of endothelial dys-
function were higher in patients with veno-occlusion
disease (VOD), engraftment syndrome, or GVHD.
Further studies are planned with increased patient
samples to improve statistical confidence and deter-
mine which of these proteins may serve as suitable
diagnostic or prognostic markers.
Insights from these in vivo data were brought to
a laboratory-based macrovascular cell model [3] to
more deeply explore the effects soluble plasma factors
released after HSCT have on resting endothelium.
Using this system, plasma obtained following both
auto- and allo-HSCT resulted in EC activation as
characterized by an increase in the expression of cell
surface adhesion receptors, leukocyte adhesion follow-
ing exposure to circulating blood, and the activation of
the p38 mitogen-activated protein kinase (MAPK).
When additional pro-thrombotic effects were evalu-
ated, increased adhesion of platelets was observed
when the extracellular matrix (ECM) was exposed toblood under flow conditions. This effect was only ob-
served in the allogeneic setting; and was believed to be
secondary to enrichment of the ECM with VWF.
Plasma from both the allo and the auto settings induced
cell proliferation, as measured by activation of ERK42/
44. By contrast, apoptosis, assessed by measuring
activation of the SAPK/JNK pathway, was only induced
by plasma from allogeneic HSCT recipients.
As alluded to above, most of the previous work
describing the role of endothelial injury in the develop-
ment of the HSCT-associated complications have been
carried out in the allogeneic setting [4,5]. However, the
aforementioned studies indicate that the conditions
following auto-HSCT lead to EC activation and dam-
age as well [3,6]. Furthermore, despite intriguing
observations in the macrovascular cell model, most of
the complications associate with effects on the
microvasculature. Because there are physiologic
differences between both cell types [7], the pro-
inflammatory and pro-thrombotic factors released fol-
lowing autologous HSCT were comparatively studied
using corresponding models of both the macro- and
microvascular locations. Evidence for activation and
damage was observed to a comparable degree in both
cell types, but a more reactive ECM with respect to
platelet adhesion was seen in cells of microvascular ori-
gin. This higher reactivity was characterized by in-
creases in the expression of both VWF and tissue
factor (TF) within the ECM. Because TF is a major ac-
tivator of the extrinsic pathway of blood coagulation, the
synthesis and release of this protein to the ECM may
have important thrombotic consequences at the micro-
vascular location. Interestingly, defibrotide, a medicinal
compound comprised of a mixture of oligonucleotides
derived from the controlled depolymerization of por-
cine intestinalmucosal DNA, showed a protective effect
on both cell lines by preventing the development of the
pro-inflammatory and pro-thrombotic phenotypes [8].
Several publications have described the multifaceted ef-
fects of defibrotide [9], and there is strong evidencedem-
onstrating that defibrotide is effective in the treatment
and prophylaxis of VOD. Although the precise molecu-
lar mechanisms responsible for this protective effect are
still a subject of investigation, thesedata suggest a poten-
tial effect of defibrotide on the signaling pathways in-
volving p38MAPK and Akt, which become activated
during physiologic stress.
In sum, observations generated from the ex vivo
macro- and microvascular cell model showed a strong
correlation with the kinetics of change in plasma bio-
markers of endothelial dysfunction found in the in
vivo studies. The methodology applied throughout
these investigations allows for the reproduction of dif-
ferent clinical scenarios and the evaluation of various
strategies aimed at reducing endothelial toxicity that
contributes to early, (and perhaps also late), complica-
tions of HSCT.
Biol Blood Marrow Transplant 17:S101-S108, 2011 S103Translational Research Efforts in Blood and Marrow TransplantationTRANSLATIONAL RESEARCH EFFORTS
FOR IPS
Acute pulmonary dysfunction remains a frequently
fatal complication followingHSCT. IPS defines a clin-
ical disorder characterized by signs and symptoms of
pneumonia, and evidence for widespread alveolar in-
jury in the absence of infection [10]. To better charac-
terize the clinical spectrum of disease and to more
carefully match subtypes of IPS with specific preclini-
cal models that have been developed to reproduce
and understand them, the definition of IPS has been
further classified into specific entities based on the pri-
mary anatomical sites of inflammation and dysfunction
[11]. Known risk factors shed light on possible etiolo-
gies of IPS including the injurious effects of condition-
ing regimens and immune dysregulation involving
cellular and soluble mediators of inflammation
[10,12-16]. Despite this knowledge and advances in
supportive care, outcomes remain unacceptable;
mortality rates are high, and time to death following
diagnosis is short.
Murine models have uncovered pathways of in-
flammation as a segue to the development of more ef-
fective treatment or prevention strategies for IPS
(reviewed in [11]). Experimental insights support a shift
away from the current paradigm where IPS is viewed
simply as an idiopathic clinical syndrome and toward
a process in which the lung is the target of a complex
immune-mediated attack. In this context, soluble in-
flammatory mediators like tumor necrosis factor alpha
(TNFa) are believed to be significant, albeit not exclu-
sive, effectors of IPS, and cells of both lymphoid and
myeloid origin are recruited to the lung and
contribute to inflammation.
Experimental IPS is associated with increased
TNFa in both lung tissue and bronchoalveolar lavage
fluid (BALF) [12,14,16], and several strategies have
confirmed a causal role for TNFa in the
development of IPS [16]. Furthermore, the use of
mice deficient in TNFa has shown that experimental
IPS is dependent upon donor, rather than host derived
TNFa [17]. Donor T cell-derived TNFa also regu-
lates the chemokine milieu in the lung within the first
2 weeks after HSCT, which directly contributes to the
recruitment of monocytes and neutrophils as lung in-
jury progresses [17]. The inflammatory effects of
TNFa are mediated via 2 corresponding receptors
[18]. Recent data show that although the absence of
TNFRI in allo-HSCT recipients resulted in decreased
pulmonary edema early after HSCT [19], interactions
between TNFa and TNFRII are responsible for in-
creased expression of ICAM-1 on pulmonary endothe-
lium and subsequent leukocyte recruitment and lung
inflammation [20].
In the absence of infection, increases in neutrophils
and TNFa in the lungs of mice suggest that hostmicroflora-derived lipopolysaccharide (LPS) also con-
tributes to IPS pathophysiology. LPS stimulates
TNFa release primarily via the innate immune system
[21-26]. LPS levels are elevated in the BALF of mice
with IPS, and the administration of endotoxin to
mice with advanced GVHD causes alveolar
hemorrhage [14,16]. Blocking TNFa in this setting
completely abrogates the recruitment of neutrophils
into the lungs and prevents further damage
(including hemorrhage) underscoring the
relationship between neutrophils, TNFa, and LPS
[16]. Importantly, evidence for cytokine activation
and LPS amplification is also apparent in patients
with IPS [27,28].
Although several lines of evidence support the role
of soluble effectors in the development of IPS, the
identification of specific targets of inflammation in
the lung has been elusive. Pulmonary vascular ECs
can express MHC Class I, MHC Class II, and minor
histocompatibility (H) antigens, the expression of
which is enhanced by TNFa and interferon gamma
(IFNg). As discussed, EC injury has been implicated
as a direct contributor to several complications follow-
ing allo-HSCT [29]. Clinical and experimental IPS is
associated with evidence for EC injury and increased
permeability as demonstrated by physical and radio-
graphic evidence of pulmonary edema, enhanced total
protein levels in BALF, and increased wet-to-dry lung
weight ratios in affected animals [15,27]. In fact,
leukocyte infiltration during IPS is accompanied by
significant apoptosis of the pulmonary vascular
endothelium [30]; EC apoptosis coincides with the on-
set of pulmonary pathology, is associated with eleva-
tions in BALF TNFa levels, and is accompanied by
evidence for EC activation as measured by enhanced
mRNA expression of adhesion molecules [30]. More-
over, neutralization of TNFa significantly reduces
EC apoptosis and lung histopathology observed in
mice [30]. In this light, TNFa may function as both
an effector and facilitator of lung injury by contribut-
ing directly to EC injury and by regulating the chemo-
kine milieu in the lung during the early stages of IPS.
As noted, current therapeutic strategies for IPS are
suboptimal and prospective studies addressing the
treatment of IPS, including the use of steroids, are
lacking in the literature. In a recent translational re-
search effort built upon robust preclinical data regard-
ing the role of TNFa in the development of IPS,
etanercept (Enbrel, Amgen, Thousand Oaks, CA)
was administered in combination with systemic ste-
roids and empiric antimicrobial therapy to a total of
15 patients with IPS [27]. Therapy was well tolerated
overall. Ten of the 15 patients were able to completely
withdraw from supplemental oxygen support within
28 days of therapy, and survival at day 28 and day 56
of study was significantly improved. Based upon these
encouraging results, larger phase II and phase III trials
S104 Biol Blood Marrow Transplant 17:S101-S108, 2011S. Paczesny et al.are ongoing within the Pediatric Blood and Marrow
Transplantation Consortium and Bone Marrow
Transplant Clinical Trials Network, respectively.
Plasma protein profileswere analyzed byELISAon
samples collected from study patients and controls.
Levels of proteins associated with the recruitment
(MCP-1, IL-8), activation (sCD14, LBP) and effector
function (TNFa, sTNFRI, IL-6) of macrophages,
monocytes, and neutrophils were significantly in-
creased in BAL fluid and plasma in patients with IPS
compared to HSCT controls, and these elevations re-
turned to baseline levels in responding patients [27].
Antibody array data revealed significant differences in
plasma Angiopoietin-2 levels between patients with
IPS compared to HSCT controls. Angiopoietin-1
(Ang-1) and angiopoietin-2 (Ang-2) are peptide ligands
for the receptor tyrosine kinase,Tie-2, that is expressed
on the surface of ECs.The 2 proteins are known to reg-
ulate vascular integrity. Ang-1 promotes vessel stabil-
ity, whereas Ang-2 promotes vascular permeability,
and levels of Ang-2 are increased in patients with acute
respiratory distress syndrome [31]. Plasma levels of
Ang-2 were also found to be significantly elevated in
IPS patients compared to concentrations present in
the same patients prior to the onset of symptoms and
in controls. Importantly, plasma levels of Ang-2 re-
turned to baseline in IPS patients who responded to
therapy, but continued to rise in nonresponders. Of
particular interest, Ang-2 sensitizes ECs to TNFa
and regulates TNFa-induced adhesion molecule ex-
pression [32] findings that directly support preclinical
data generated using murine IPS models. To this
end, experiments are planned to determine whether
Ang-2 may be contributing to IPS via similar mecha-
nisms. Such an endeavor will serve to bring clinical in-
sights back to the laboratory.
Consistent with animal studies, not all patients
with IPS responded to etanercept therapy. Additional
experiments using a discovery, label free, ‘‘bottom-up
approach’’ indentified several proteins that could pre-
dict, at the time of HSCT, patients who: (1) progress
to IPS and (2) respond to Enbrel therapy. Further-
more, categorizing patients with IPS based upon the
presumed anatomic site of primary injury and exploit-
ing mechanistic insights gained in the laboratory, may
avail the use of other promising, noncrossreactive
agents for the treatment of IPS. For example, it is con-
ceivable that approaches to maintain EC integrity may
be effective at preventing or treating IPS in patients
with acute inflammation and pulmonary capillary
leak. Because IPS develops and can progress to respira-
tory failure despite significant systemic immunosup-
pression, strategies to inhibit pathways of leukocyte
recruitment to the lung may also serve as adjuncts to
standard therapy particularly if disease onset is later
and inflammation by cellular, (rather than soluble ef-
fectors) predominates. Finally, future studies examin-ing the role of surfactant replacement therapy,
perhaps in combination with etanercept, might prove
useful in overcoming the effects of epithelial injury
and dysfunction on ventilation and oxygenation.NEW DISCOVERIES IN PROTEOMICS AND
GRAFT-VERSUS-HOST DISEASE
New diagnostic and predictive monitoring tools
are still needed to optimize the delivery of care to
HSCT recipients and improve outcomes. The past
decades have been characterized by an explosive
evolution of ‘‘omics’’ technologies, largely because of
important advances in chemistry, engineering, high-
throughput technical devices, and bioinformatics.
These tools have allowed the elucidation of the impor-
tance of epigenetics on DNA transcription, transcrip-
tional regulation through microRNA (miRNA) or
small interfering RNA (siRNA), posttranslational
modifications, and regulation at the metabolic level.
In the final segment of this review, GVHD will be
used as a model to explore some of the opportunities
that molecular diagnostic tools can offer translational
research efforts in HSCT.
The classic paradigm that DNA determines the
fate of the cell is currently being questioned, as com-
plex regulatory processes at the level of both transcrip-
tion and translation are better appreciated. Indeed, the
study of complete sets of molecules (omics) with expo-
nential speed, accuracy, and cost-effectiveness now en-
ables researchers to gain insight into the mechanism of
diseases, with fewer a priori assumptions [33]. Because
proteins are more proximate than other cellular
metabolites to the ongoing pathophysiology of this
disease, the use of proteomics for the molecular diag-
nosis of GVHD and the development of suitable bio-
markers has been an area of intense interest [34,35].
Although the identification of individual proteins by
proteomics methods in complex biological fluids has
historically been limited, the emergence of new tools
such as tandem mass spectrometry (MS/MS) and
computational analysis has made it possible to detect
and identify interacting proteins within a signaling
network.
Proteomics technologies are currently used in 2
related areas: biomarker discovery, and the elucidation
of pathologic processes to identify novel therapeutic
targets. The paucity of validated biomarkers for
GVHD is partly because of the complex pathology
of GVHD that involves distinct sequential phases of
immune system cellular activation and cytokine pro-
duction, which would be expected to influence specific
cellular and protein levels in the GVHD patient blood
[36]. GVHD is a systemic immunologic disorder that
also affects specific organ systems, including the
gastrointestinal (GI) tract, liver, and skin. Clinical
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distinguish from other causes. Thus, biomarkers that
are GVHD and target organ specific may also improve
the diagnosis of HSCT complications.
The blood is the most frequently analyzed bodily
component, and the ease with which it can be sampled
makes it a logical choice for biomarker applications.
The levels of individual blood proteins represent
a summation of multiple events that occur in every or-
gan system. In this regard, a comprehensive assessment
of plasma protein levels might provide an integrated
view of a systemic disease such as GVHD. In a seminal
report, the identification of the GVHD proteome was
approached via multiplexed protein measurements
using antibody microarrays. Patient plasma samples
were screened by competitive hybridization to anti-
body arrays specific for 120 diverse proteins, including
acute phase reactants, cytokines, angiogenic factors,
leukocyte adhesion molecules, metalloproteinases,
and their inhibitors. This approach identified and val-
idated a 4-biomarker (IL-2Ra, tumor necrosis factor
receptor 1 [TNFR1], hepatocyte growth factor
[HGF], and IL-8) panel that discriminated GVHD-
negative from GVHD-positive patients. Importantly,
the number of patient samples allowed for the first
demonstration that these biomarkers are associated
with the clinical outcome and prognosis of GVHD.
To overcome the limitations of antibody arrays and
create a broader, less-biased method for characterizing
a GVHD-specific proteome, a state-of-the-art proteo-
mic technology that is gel-free, and based on high-
resolution mass spectrometry was employed. This
technique infers complex proteomes present in sam-
ples, such as plasma, by matching mass spectra to a se-
quence database to identify proteins using the Intact
Protein Analysis System (IPAS). In these experiments,
GVHD-negative and GVHD-positive pools were in-
dividually immunodepleted of the 6 most abundant
plasma proteins, labeled, recombined and ultimately
subjected to a 2-dimensional protein fractionation pro-
cedure. The individual fractions were then digested
and analyzed on a LTQ-FT mass spectrometer. The
acquired spectra were automatically processed by the
high-throughput Computational Proteomics Analysis
System to identify proteins in the sample, with a false
discovery rate of\5% [37] and the identification of
proteins with a range of concentrations spanning 7
logs [38]. The list of proteins identified by MS/MS
was sequentially prioritized based on their degree of
dysregulation, type (with focus on cell surface glyco-
proteins and the secretome), uniqueness toGVHD tar-
get organs and the availability of sandwich ELISA
antibodies. A schematic of these 3 proteomics strate-
gies for discovery of GVHD biomarkers is shown in
Figure 1.
Because biomarkers present at the time of diagno-
sis of GVHD might be target organ dependent, theidentification of tissue specific biomarkers was ex-
plored. To accomplish this, IPAS was used to compare
plasma pooled from ten patients with skin-specific
GVHD to that from 10 controls, and plasma pooled
from 10 patients with GI tract-specific GVHD to 10
additional controls in a second IPAS run. In total,
834 proteins in the skin GVHD comparison and 639
in the GI GVHD comparison were quantified. The
list of candidate proteins was refined using the process
explained above, and ultimately, 4 skin proteins (elafin,
lipopolysaccharide-binding protein, galectin 3-bind-
ing protein, and CD163) and 3 GI proteins (regenerat-
ing islet-derived 1 alpha [REG1a], REG3a, and
carcinoembryonic antigen-related cell adhesion mole-
cule 1 [CEACAM1]) were selected for further valida-
tion. Levels of the 3 GI GVHD candidates were
measured by ELISA in 570 allogeneicHCT recipients,
and were significantly higher in plasma from patients
with GI-specific GVHD than in control samples
from patients without GVHD, with skin-specific
GVHD, or with non-GVHD enteritis (unpublished
data).
Elafin emerged as the lead biomarker candidate of
skin GVHD at the time of clinical diagnosis because it
is (1) highly expressed in skin tissue, (2) induced by
TNFa [39] and (3) overexpressed in diseases such as
psoriasis. Indeed, when measured by ELISA in 492
allogeneic HCT recipients, levels of elafin were signif-
icantly higher in plasma from patients with skin-
specific GVHD compared to samples from patients
without GVHD, with GI-specific GVHD, or with
non-GVHD rash. Importantly, elafin concentrations
were also found to have prognostic significance for
patients with GVHD of the skin. The NRM at 1
year was more than double in the high-elafin group
($6000 pg/mL, n 5 79) as opposed to the low-elafin
group (\6000 pg/mL, n 5 80), 28% versus 11%,
and the 5-year overall survival (OS) was significantly
higher in the low-elafin group than in the high-elafin
group: 48% versus 26% [40].FUTURE CHALLENGES AND
OPPORTUNITIES
GVHD, IPS, and SOS remain frequent and severe
complication of allogeneic HSCT, and despite signif-
icant advances in critical care medicine, mortality rates
remain unacceptably high with standard therapy. The
use of preclinical models has proved valuable in
defining specific contributors to the inflammation en-
gendered during IPS and GVHD, and laboratory in-
sights are actively being translated back to the clinic
in open trials in adult and pediatric HSCT recipients.
It is anticipated that evaluation of the plasma proteome
of human samples will foster new lines of investigation
in the laboratory and form the basis for future
Figure 1. Overview of 3 proteomics strategies used for discovery of GVHD biomarkers (1) Differential in-gel electrophoresis (DIGE). Pooled plasma
samples from GVHD-negative and GVHD-positive individuals are labeled with 2 fluorescent dyes, combined, and separated in a 2-dimensional gel by
charge and molecular weight, followed by HPLC to separate proteins based on hydrophobicity. Spots of interest are picked and digested with trypsin
for identification by mass spectrometry. (2) Antibody arrays. Plasma samples fromGVHD-negative and GVHD-positive individuals are combined to form
a reference pool, which is labeled with Biotin-ULS (red). A second aliquot of each individual plasma sample is labeled with Fluorescein-ULS (green). The
labeled plasma proteins from 1 individual sample and 1 aliquot of the reference pool are hybridized to each side of the antibody array overnight. After
repeated washes, the arrays are probed with the fluorescent reporter molecules streptavidin-DY647 and antifluorescein-DY547, washed, dried, and
scanned at 2 wavelengths within 24-48 hours before bioinformatic analysis. (3) Intact Protein Analysis System. Plasma samples from ten GVHD-
positive patients and 10 GVHD-negative patients are independently pooled. Pools are individually immunodepleted of albumin, IgG, IgA, transferrin,
haptoglobin, and antitrypsin, and intact proteins are labeled at cysteine residues with acrylamide. The GVHD-negative pool receives the light C12-
acrylamide isotope and the GVHD-positive pool receives the heavy C13-acrylamide isotope. The pools aremixed together for analysis by anion exchange
chromatography, reverse-phase chromatography, and LC-MS/MS. The spectra are automatically processed by the Computational Proteomics Analysis
System to identify individual proteins.
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deed, proteomics tools give insights into the patho-
logic processes that may help identify novel
therapeutic targets. Collectively, data provided herein
provide a proof-of-principle demonstration that bio-
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ment. Such information has transformative potential
regarding our approach to patient care; as our under-
standing of pathways involved with the development
of IPS and GVHD evolve, determining which patient
will respond best to the new agents available in the
therapeutic armamentarium will be critical to improv-
ing outcomes for our patients.ACKNOWLEDGMENTS
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